Avidity Biosciences (RNA) News Today → The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad) Free RNA Stock Alerts $23.91 0.00 (0.00%) (As of 04/16/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineUnveiling the key role of RNA modification in HIV-1 survival and replicationmsn.com - April 13 at 8:29 AMAvidity Biosciences (NASDAQ:RNA) Rating Reiterated by Needham & Company LLCamericanbankingnews.com - April 13 at 6:16 AMVanguard Group Inc. Acquires 47,305 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA)marketbeat.com - April 13 at 4:31 AMAnalysts Offer Insights on Healthcare Companies: Carisma Therapeutics (CARM), Avidity Biosciences (RNA) and Vera Therapeutics (VERA)markets.businessinsider.com - April 11 at 1:39 PMSG Americas Securities LLC Invests $377,000 in Avidity Biosciences, Inc. (NASDAQ:RNA)marketbeat.com - April 8 at 4:09 AMArthur A. Levin Sells 20,000 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA) Stockinsidertrades.com - April 5 at 5:04 AMAvidity Biosciences (NASDAQ:RNA) Shares Down 2.7% Following Insider Sellingmarketbeat.com - April 4 at 11:55 AMInsider Sell: Avidity Biosciences Inc (RNA) President and CEO Sarah Boyce Sells 28,000 Sharesfinance.yahoo.com - April 4 at 11:11 AMAvidity Biosciences, Inc. (NASDAQ:RNA) Director Arthur A. Levin Sells 20,000 Sharesmarketbeat.com - April 3 at 9:19 PMAvidity Biosciences (NASDAQ:RNA) Hits New 52-Week High at $26.62marketbeat.com - April 1 at 5:51 PMAvidity Biosciences to Participate in Upcoming Investor Conferencesprnewswire.com - March 27 at 9:00 AMRNA Apr 2024 17.500 callfinance.yahoo.com - March 17 at 5:14 AMRNA Apr 2024 17.500 putfinance.yahoo.com - March 16 at 12:35 PMAvidity Biosciences, Inc. (NASDAQ:RNA) CFO Sells $980,800.00 in Stockinsidertrades.com - March 16 at 8:42 AMRNA Apr 2024 22.500 callfinance.yahoo.com - March 16 at 2:35 AMInsider Sell: CFO Michael Maclean Sells 40,000 Shares of Avidity Biosciences Inc (RNA)finance.yahoo.com - March 15 at 9:34 PMInsider Selling: Avidity Biosciences, Inc. (NASDAQ:RNA) CFO Sells 40,000 Shares of Stockmarketbeat.com - March 15 at 4:46 PMAvidity Biosciences (NASDAQ:RNA) Coverage Initiated at Cantor Fitzgeraldmarketbeat.com - March 14 at 8:38 AMAvidity Biosciences, Inc. (NASDAQ:RNA) Director Sells $608,931.23 in Stockinsidertrades.com - March 13 at 6:40 AMInsider Selling: Avidity Biosciences, Inc. (NASDAQ:RNA) Director Sells 27,641 Shares of Stockmarketbeat.com - March 12 at 10:29 PMAvidity Biosciences (NASDAQ:RNA) Reaches New 1-Year High at $22.55marketbeat.com - March 12 at 3:36 PMAdage Capital Partners GP L.L.C. Boosts Stake in Avidity Biosciences, Inc. (NASDAQ:RNA)marketbeat.com - March 10 at 6:37 AMAvidity Biosciences (NASDAQ:RNA) Trading 6.2% Higher marketbeat.com - March 8 at 12:43 PMChardan Capital Weighs in on Avidity Biosciences, Inc.'s FY2024 Earnings (NASDAQ:RNA)marketbeat.com - March 8 at 7:21 AMAvidity Biosciences, Inc. (NASDAQ:RNA) Receives Consensus Recommendation of "Buy" from Brokeragesmarketbeat.com - March 8 at 3:25 AMAvidity Biosciences: Strong Buy Rating Amidst Positive Clinical Developments and Price Target Surgemarkets.businessinsider.com - March 7 at 4:53 PMGSA Capital Partners LLP Has $2.17 Million Position in Avidity Biosciences, Inc. (NASDAQ:RNA)marketbeat.com - March 7 at 9:45 AMAvidity Biosciences, Inc. (NASDAQ:RNA) to Post Q1 2024 Earnings of ($0.78) Per Share, Leerink Partnrs Forecastsmarketbeat.com - March 7 at 6:40 AMAvidity Biosciences: Targeting A First Ever Approval In DM1 With Improving Dataseekingalpha.com - March 5 at 1:27 PMA Closer Look at 5 Analyst Recommendations For Avidity Biosciencesmarkets.businessinsider.com - March 5 at 7:58 AMBuy Rating Affirmed for Avidity Biosciences Following Promising MARINA-OLE Study Data and RNA Analysismarkets.businessinsider.com - March 5 at 2:58 AMBuy Rating Affirmed: Avidity Biosciences’s Promising MARINA-OLE Trial Data Indicates Significant DM1 Treatment Breakthroughmarkets.businessinsider.com - March 4 at 4:52 PMAvidity Biosciences Says Lead Program Shows Reversal Of Disease Progression In Neuromuscular Diseasemsn.com - March 4 at 4:52 PMAvidity Accelerates Phase 3 HARBOR Study Initiation To Q2 - Quick Factsmarkets.businessinsider.com - March 4 at 11:51 AMAvidity Biosciences Announces Positive AOC 1001 Long-term Data Showing Reversal of Disease Progression in People Living with Myotonic Dystrophy Type 1 Across Multiple Endpoints; Same Key Endpoints Agreed for Phase 3 HARBOR™ Trialfinance.yahoo.com - March 4 at 11:51 AMTop 2% Biotech Avidity Collapses Despite 'Positive' Results In Treating Muscular Dystrophyfinance.yahoo.com - March 4 at 11:51 AMAvidity Biosciences secures $400 million in private placementinvesting.com - March 2 at 5:33 PMAvidity Biosciences (NASDAQ:RNA) Stock Price Up 9.2%marketbeat.com - March 1 at 3:14 PMLeerink Partnrs Comments on Avidity Biosciences, Inc.'s FY2025 Earnings (NASDAQ:RNA)marketbeat.com - March 1 at 8:45 AMAvidity Biosciences Full Year 2023 Earnings: Misses Expectationsfinance.yahoo.com - March 1 at 8:39 AMProfund Advisors LLC Cuts Stock Holdings in Avidity Biosciences, Inc. (NASDAQ:RNA)marketbeat.com - March 1 at 6:26 AMAvidity Biosciences Incedition.cnn.com - February 29 at 8:17 PMAvidity Biosciences: DMD Advancement And 2024 Catalysts Make It A Must-Watchseekingalpha.com - February 29 at 3:17 PMAvidity Biosciences Honors Rare Disease Day®prnewswire.com - February 29 at 12:00 PMAvidity Biosciences, Inc.: Avidity Biosciences Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Highlightsfinanznachrichten.de - February 29 at 10:16 AMTD Cowen Reaffirms Their Buy Rating on Avidity Biosciences (RNA)markets.businessinsider.com - February 29 at 10:16 AMAvidity Biosciences Announces Oversubscribed $400 Million Private Placementprnewswire.com - February 29 at 7:00 AMFmr LLC Buys 491,567 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA)marketbeat.com - February 29 at 5:29 AMAvidity Biosciences Inc (RNA) Reports Year-End Financials and Clinical Progressfinance.yahoo.com - February 29 at 12:01 AMAvidity Biosciences to Participate in Upcoming Investor Conferencesprnewswire.com - February 27 at 9:00 AM Get Avidity Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for RNA and its competitors with MarketBeat's FREE daily newsletter. Email Address The “Perfect Storm” for Gold (Ad)Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025. Click here now to download the free Precious Metals Buying Guide! RNA Media Mentions By Week RNA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RNA News Sentiment▼0.690.66▲Average Medical News Sentiment RNA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RNA Articles This Week▼53▲RNA Articles Average Week Get Avidity Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for RNA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Amphastar Pharmaceuticals News Today Syndax Pharmaceuticals News Today Structure Therapeutics News Today Schrödinger News Today Vera Therapeutics News Today Janux Therapeutics News Today Galapagos News Today Catalyst Pharmaceuticals News Today PTC Therapeutics News Today Geron News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RNA) was last updated on 4/16/2024 by MarketBeat.com Staff From Our PartnersCan't believe it's happening againManward PressHe Is Giving Away BitcoinCrypto Swap ProfitsThe "Smart Money" Is Ready for May 1st Are You?Stansberry ResearchThe “Perfect Storm” for GoldGold Safe Exchange1970’s computer coder issues shocking A.I. warningTradeSmithTop 5 AI Stocks to Buy for 2024Market Moving TrendsYou won't believe what Citigroup just did to it's depositorsAmerican AlternativeOptions trading has suddenly become more reliable.Eagle Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avidity Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.